150 related articles for article (PubMed ID: 26924278)
21. Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma.
Jamshidi N; Margolis DJ; Raman S; Huang J; Reiter RE; Kuo MD
Radiology; 2017 Jul; 284(1):109-119. PubMed ID: 28453432
[TBL] [Abstract][Full Text] [Related]
22. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer.
Hakimi JM; Schoenberg MP; Rondinelli RH; Piantadosi S; Barrack ER
Clin Cancer Res; 1997 Sep; 3(9):1599-608. PubMed ID: 9815849
[TBL] [Abstract][Full Text] [Related]
23.
Siraj AK; Masoodi T; Bu R; Pratheeshkumar P; Al-Sanea N; Ashari LH; Abduljabbar A; Alhomoud S; Al-Dayel F; Alkuraya FS; Al-Kuraya KS
Gut; 2018 Apr; 67(4):663-671. PubMed ID: 28183795
[TBL] [Abstract][Full Text] [Related]
24. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
25. High-resolution melting analysis of MED12 mutations in uterine leiomyomas in Chinese patients.
Wang H; Ye J; Qian H; Zhou R; Jiang J; Ye L
Genet Test Mol Biomarkers; 2015 Mar; 19(3):162-6. PubMed ID: 25615570
[TBL] [Abstract][Full Text] [Related]
26. Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas.
McGuire MM; Yatsenko A; Hoffner L; Jones M; Surti U; Rajkovic A
PLoS One; 2012; 7(3):e33251. PubMed ID: 22428002
[TBL] [Abstract][Full Text] [Related]
27. p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer.
Schlechte H; Lenk SV; Löning T; Schnorr D; Rudolph BD; Ditscherlein G; Loening SA
Eur Urol; 1998; 34(5):433-40. PubMed ID: 9803007
[TBL] [Abstract][Full Text] [Related]
28. Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population.
Oh JJ; Lee SJ; Hwang JY; Kim D; Lee SE; Hong SK; Ho JN; Yoon S; Sung J; Kim WJ; Byun SS
Oncotarget; 2017 Jul; 8(27):43934-43943. PubMed ID: 28380453
[TBL] [Abstract][Full Text] [Related]
29. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
30. Distribution of MED12 mutations in fibroadenomas and phyllodes tumors of the breast--implications for tumor biology and pathological diagnosis.
Pfarr N; Kriegsmann M; Sinn P; Klauschen F; Endris V; Herpel E; Muckenhuber A; Jesinghaus M; Klosterhalfen B; Penzel R; Lennerz JK; Weichert W; Stenzinger A
Genes Chromosomes Cancer; 2015 Jul; 54(7):444-52. PubMed ID: 25931199
[TBL] [Abstract][Full Text] [Related]
31. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors.
Schwetye KE; Pfeifer JD; Duncavage EJ
Hum Pathol; 2014 Jan; 45(1):65-70. PubMed ID: 24196187
[TBL] [Abstract][Full Text] [Related]
32. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
[TBL] [Abstract][Full Text] [Related]
33. Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing.
Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2015 Jul; 152(2):305-12. PubMed ID: 26093648
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.
Park MJ; Shen H; Spaeth JM; Tolvanen JH; Failor C; Knudtson JF; McLaughlin J; Halder SK; Yang Q; Bulun SE; Al-Hendy A; Schenken RS; Aaltonen LA; Boyer TG
J Biol Chem; 2018 Mar; 293(13):4870-4882. PubMed ID: 29440396
[TBL] [Abstract][Full Text] [Related]
35. MED12 exon 2 mutation as a highly sensitive and specific marker in distinguishing phyllodes tumours from other spindle neoplasms of the breast.
Lien HC; Huang CS; Yang YW; Jeng YM
APMIS; 2016 May; 124(5):356-64. PubMed ID: 26860948
[TBL] [Abstract][Full Text] [Related]
36. Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Reporting Bioinformatics Description and Recurrent Mutations.
Salmaninejad A; Ghadami S; Dizaji MZ; Golchehre Z; Estiar MA; Zamani MR; Ebrahimzadeh-Vesal R; Nowroozi MR; Shakoori A
Clin Lab; 2015; 61(7):749-59. PubMed ID: 26299074
[TBL] [Abstract][Full Text] [Related]
37. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
[TBL] [Abstract][Full Text] [Related]
38. Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.
Otsuji K; Sasaki T; Tanabe M; Seto Y
Br J Cancer; 2021 Jan; 124(2):466-473. PubMed ID: 33046803
[TBL] [Abstract][Full Text] [Related]
39. Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.
Volckmar AL; Leichsenring J; Flechtenmacher C; Pfarr N; Siebolts U; Kirchner M; Budczies J; Bockmayr M; Ridinger K; Lorenz K; Herpel E; Noske A; Weichert W; Klauschen F; Schirmacher P; Penzel R; Endris V; Stenzinger A
Genes Chromosomes Cancer; 2017 Jan; 56(1):11-17. PubMed ID: 27438523
[TBL] [Abstract][Full Text] [Related]
40. PTEN Loss in a Prostate Cancer Cohort From Jordan.
Al Bashir S; Alzoubi A; Alfaqih MA; Kheirallah K; Smairat A; Haddad H; Al-Dwairy A; Fawwaz BAB; Alzoubi M; Trpkov K
Appl Immunohistochem Mol Morphol; 2020; 28(5):389-394. PubMed ID: 30614821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]